Cerebral Microbleeds and Amyloid Pathology Estimates From the Amyloid Biomarker Study

Elisabeth Oomens, Julie; van Gils, Veerle; J. B. Vos, Stephanie; M. Freeze, Whitney; N. Maserejian, Nancy; Curiale, Gioacchino; Gillis, Cai; Boada, Merçé; M. van der Flier, Wiesje; Hort, Jakub; C. Johnson, Sterling; Lleó, Alberto; H. Ramakers, Inez; M. Rodrigue, Karen; Sánchez‐Juan, Pascual; Sarazin, Marie; Scarmeas, Nikolaos; Zetterberg, Henrik; Alcolea, Daniel; Barkhof, Frederik; Blennow, Kaj; Bottlaender, Michel; den Braber, Anouk; Cerman, Jiří; Drake-Pérez, Marta; Fortea, Juan; Handels, Ron; Ingala, Silvia; Jiménez‐Bonilla, J.; Karavasilis, Stratos; Lagarde, Julien; Legdeur, Nienke; Lorenzini, Luigi; Marquié, Marta; Moonen, Justine; Olivieri, Pauline; Orellana, Adelina; Ossenkoppele, Rik; A. Rivera‐Rivera, Leonardo; Rodríguez‐Rodríguez, Eloy; Ruiz Laza, Agustín; E. Teunissen, Charlotte; M. Tijms, Betty; Velonakis, Georgios; R.J. Verhey, Frans; Jelle Visser, Pieter; J. Jansen, Willemijn; ACE Healthy Brain Initiative (FACEHBI) Study Group, Fundació; Study Group, BIOFACE

doi:10.1001/jamanetworkopen.2024.55571

Public

Cerebral Microbleeds and Amyloid Pathology Estimates From the Amyloid Biomarker Study

Published in JAMA Network Open • Jan 22, 2025

Authors:

Julie Elisabeth Oomens

Veerle van Gils

Stephanie J. B. Vos

Abstract

Importance: Baseline cerebral microbleeds (CMBs) and APOE ε4 allele copy number are important risk factors for amyloid-related imaging abnormalities in patients with Alzheimer disease (AD) receiving therapies to lower amyloid-β plaque levels. Objective: To provide prevalence estimates of any, no mor...

Subject

Dementia

Pittsburgh compound B

Medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!